← ANALYST RATINGS · TIPRANKS
Palisade Bio (PALI): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $13.33, the highest $25.00, the lowest $7.00. The average is +845.6% from the last price of $1.41.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $7.00 | Buy | +396.5% | Reiterated | 13.10.26on TipRanks 06:26 | −7.9%next day +2.1% | ↗ |
| Name not given | — | $6.00 | Buy | +325.5% | Initiated | 08.10.26on TipRanks Oct 11 09:55 | −1.6%next day +5.6% · 5 days +6.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Sell | +6.4% | Downgrade | 26.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | +6.4% | Upgrade | 26.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +6.4% | Reiterated | 26.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 | Hold | +6.4% | Reiterated | 26.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +6.4% | Reiterated | 26.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Sell | +6.4% | Downgrade | 26.09.26on TipRanks 03:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $25.00 | Buy | +1,673.0% | Reiterated | 23.09.26on TipRanks Sep 24 02:45 | −4.6%next day −1.8% · 5 days −15.0% | ↗ |
| Unknown Analyst | B. Riley Securities | $7.00 | Buy | +396.5% | Initiated | 12.08.26on TipRanks 08:30 | −8.7%next day +9.0% · 5 days +10.6% | ↗ |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $8.00 | Buy | +467.4% | Reiterated | 12.08.26on TipRanks 08:30 | −8.7%next day +9.0% · 5 days +10.6% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $8.00 | Buy | +467.4% | Reiterated | 11.08.26on TipRanks 07:55 | +2.2%next day −8.7% · 5 days −4.3% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $5.00 | Buy | +254.6% | Reiterated | 06.07.26on TipRanks 01:55 | −3.7%next day +2.4% · 5 days −7.1% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $7.00 | Buy | +396.5% | Initiated | 08.04.26on TipRanks 16:45 | +5.3%next day −8.0% · 5 days +14.5% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $12.00 | Buy | +751.1% | Reiterated | 31.03.26on TipRanks Apr 1 08:40 | −4.6%next day +6.7% · 5 days +2.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Palisade Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.00 at a price of $1.35 (+640.7%); now: $10.17 at $1.41 (+621.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 4 | 5 | 6 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.07 to $-0.05). Last quarter: $-0.05.
Best top-analyst consensus in the sector · Healthcare
About Palisade Bio
- CEO: J. D. Finley
- Employees: 14
- 4600 South Syracuse Street, Denver, CA, 80237, US
- www.palisadebio.com
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Data from the stock’s TipRanks forecast page, read 93 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗